Abstract: TH-PO1250
Telitacicept in Patients with Refractory IgA Nephropathy: A Randomized, Open-Label Clinical Trial
Session Information
- Late-Breaking Research Posters
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2202 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Authors
- Liu, Shang, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China
- Cai, Hong, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China
- Yan, Jiayi, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China
- Gu, Leyi, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China
- Mou, Shan, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China
- Wang, Qin, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China
Background
Refractory IgA nephropathy has poor prognosis with limited therapies. Telitacicept inhibits BLyS/APRIL for autoimmune rheumatic diseases. This investigator-initiated trial evaluated its efficacy and safety in refractory IgAN.
Methods
63 patients from 4 renal centers received 24-week treatment, randomized to telitacicept plus supportive care (36 patients) or supportive care alone (27 patients). Primary endpoint: relative reduction in 24-h proteinuria; secondary endpoints: adverse events, eGFR, urine protein-creatinine ratio.
Results
18/36 TTXP patients achieved complete or partial remission. At week 24, proteinuria decreased by 48.09% from baseline in the TTXP arm, while proteinuria remained unchanged in controls. Renal function differed significantly between groups: eGFR changed +1.27% (95% CI −5.46, 9.30) in the TTXP group versus −10.19% (95% CI −18.33, 1.20) in controls (P=0.001). Among patients with moderate-severe renal injury, telitacicept reduced proteinuria by 31.87% at week 12 and 45.95% at week 24. The Oxford MEST-C NOS+Adh+ subgroup showed a trend toward better clinical response. Adverse event rates were similar in both groups.
Conclusion
Telitacicept delivers superior proteinuria-lowering efficacy with matched safety versus supportive care, offering a promising new therapy for refractory IgA nephropathy.